Roche purchases shares in tender offer for Spark Therapeutics, Inc.

Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that Roche’s wholly owned subsidiary 022019 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Spark, at a price of USD 114.50 per share in ca sh.  The tender offer expired at 5:00 p.m., New York City time, on 16 December 2019 and was not extended. Roche has been advised by Citibank, N.A., the depositary for the tender offer, that a total of approximately 23,276,342 shares of Spark ’s common stock were validly tendered and not validly withdrawn in the tender offer, which represent approximately 60.4% of the total number of shares of Spark’s common stock outstanding. Roche intends to complete the acquisition of Spark today through a merger of 022019 Merger Subsidiary, Inc. with and into Spark without a vote or meeting of Spark ’s shareholders. In the merger, all shares of Spark not owned by Spark, Roche or Roche’s wholly owned subsidiaries (other than shares as to which appraisal rights have been validly exercised under Delaware law) will be converted into the right to receive the same cash consideration per share, le ss any applicable withholding taxes, as was paid in the tender offer. Following completion of the merger, Spark will become a wholly owned subsidiary of Roche and Spark’s shares will cease to...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news